Search
talimogene laherparepvec (Imlygic)
Indications:
- unresectable cutaneous melanoma [1]
Contraindications:
- pregnancy
- immunosuppression
Dosage:
- intratumoral immunotherapy [2]
Adverse effects:
- chills, fever
- nausea
- fatigue
- injection-site pain
- HSV1 infection
Mechanism of action:
- genetically modified live herpes simplex virus type 1 (HSV1)
- does improve overall survival or benefit patients metastatic melanoma
Notes:
- expected cost: $65,000 [1]
General
antineoplastic agent (chemotherapeutic agent)
References
- FDA News Release. October 27, 2015
FDA approves first-of-its-kind product for the treatment of
melanoma.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm
- Amgen News Release. October 27, 2015
FDA Approves IMLYGIC (Talimogene Laherparepvec) As First
Oncolytic Viral Therapy In The US.
https://www.amgen.com/media/news-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us/
- Fuerst ML
Gregory Goldmacher, MD, PhD, MBA, on New Response Criteria for Intratumoral
Immunotherapy - New response criteria developed for intratumoral immunotherapy
clinical trials
MedPage Today. ASCO Reading Room 08.06.2020
https://www.medpagetoday.com/reading-room/asco/immunotherapy/87918